lung

The chart shows the growth of an initial investment of $10,000 in lung, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Every 3 months.

As of Apr 11, 2026, the lung returned -4.20% Year-To-Date and 39.48% of annualized return in the last 10 years.

Based on dividend-adjusted daily data since Aug 8, 2015, lung's average daily return is +0.13%, while the average monthly return is +4.00%. At this rate, an investment would double in approximately 1.5 years.

Historically, 62% of months were positive and 38% were negative. The best month was Feb 2016 with a return of +60.1%, while the worst month was Mar 2020 at -21.3%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 5 months.

On a daily basis, lung closed higher 54% of trading days. The best single day was Feb 11, 2016 with a return of +19.0%, while the worst single day was Mar 12, 2020 at -17.9%.

lung has an annualized alpha of 23.47%, beta of 1.31, and R² of 0.52 versus S&P 500 Index. Calculated based on daily prices since August 08, 2015.

• This portfolio captured 198.73% of S&P 500 Index gains but only 87.47% of its losses — a favorable profile for investors.
• This portfolio generated an annualized alpha of 23.47% versus S&P 500 Index — delivering returns beyond what market exposure alone would predict.

lung has an expense ratio of 0.30%, placing it in the medium range. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.

lung ranks 13 for risk / return — in the bottom 13% of portfolios on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

lung Sharpe ratios as of Apr 11, 2026 (values are recalculated daily):

• 1-Year: 1.83
• 5-Year: 0.45
• 10-Year: 1.24
• All Time: 1.39

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

Compared to the broad market, where average Sharpe ratios range from 2.14 to 3.05, this portfolio's current Sharpe ratio places it in the bottom 25%. This suggests weaker risk-adjusted returns than most portfolios, possibly due to lower returns, higher volatility, or both. It may be worth reviewing the allocation. You can use the Portfolio Optimization tool to explore options for improving the Sharpe ratio.

The chart below shows the rolling Sharpe ratio of lung compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.

lung provided a 0.41% dividend yield over the last twelve months.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the lung. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the lung was 46.87%, occurring on Dec 28, 2022. Recovery took 414 trading sessions.

The current lung drawdown is 11.30%.

The chart below shows the rolling one-month volatility.